DNA gyrase inhibitor targets M. tuberculosis
IN BRIEF
02 September 2022
The treatment of Mycobacterium tuberculosis requires long-term antibiotics, leading to poor compliance and antibiotic resistance. To identify potential new antimicrobials, Imai et al. screen a panel of Photorhabdus and Xenorhabdus nematode symbiont strains against M. tuberculosis, discovering evybactin, a novel cyclic depsipeptide that potently and selectively inhibits M. tuberculosis. Mechanistically, evybactin is transported into the cell via the ABC transporter BacA, where it targets DNA gyrase. This antimicrobial acts at an allosteric site known to be targeted by synthetic thiopene agents, distinguishing its mode of action from fluoroquinolone antibiotics.
Access options
Subscription info for Chinese customers
We have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
Additional access options:
doi: https://doi.org/10.1038/d41573-022-00149-4
Jobs
留言 (0)